# Schizophrenia Trial of Aripiprazole

> **NCT00237913** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 700 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Olanzapine or Quetiapine or Risperidone

## Key facts

- **NCT ID:** NCT00237913
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 700 (—)
- **Last updated:** 2013-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237913, "Schizophrenia Trial of Aripiprazole". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00237913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*